论文部分内容阅读
目的对恶性滋养细胞肿瘤2000年国际妇产科联盟(FIGO)预后评分标准进行初步评价。方法恶性滋养细胞肿瘤患者223例,治疗前除临床分期外,按2000年FIGO预后评分标准判定其高危因素,评价以此选择治疗方式的合理性。结果78例绒毛膜癌患者中,43例为高危,35例为低危;145例侵蚀性葡萄胎患者中,7例为高危,138例为低危。初治化疗的原则为低危患者以单药化疗为主,高危患者采用多药联合化疗。本组患者的1年、3年、5年生存率分别为986%、981%及971%。无一例因毒副反应或并发症而死亡。结论恶性滋养细胞肿瘤患者根据2000年FIGO预后评分标准选择治疗方案,取得较满意的治疗结果。
OBJECTIVE: To evaluate the prognostic score of the 2000 International Association of Gynecology and Obstetrics (FIGO) for malignant trophoblastic tumor. Methods Totally 223 patients with malignant trophoblastic tumor were enrolled in this study. Before treatment, except the clinical stage, according to 2000 FIGO prognostic criteria, the risk factors were evaluated and the rationality of treatment was evaluated. Results Of the 78 patients with choriocarcinoma, 43 were at high risk and 35 were at low risk. Of 145 patients with invasive hydatidiform mole, 7 were at high risk and 138 were at low risk. The principle of naive chemotherapy for low-risk patients with single-agent chemotherapy, high-risk patients with multi-drug combination chemotherapy. The 1-year, 3-year and 5-year survival rates of this group of patients were 986%, 981% and 971%, respectively. No case of death due to side effects or complications. Conclusion Malignant gestational trophoblastic tumor patients choose the treatment plan according to the FIGO prognosis score in 2000, and obtain satisfactory treatment results.